Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 978 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombus; Embolism Clear all
Completed Not applicable Interventional Results available

Using Intravenous Heparin Versus Standard of Care Subcutaneous Heparin to Prevent Clots After Surgery

NCT01608906
View directory record Official record
Conditions
Venous Thrombosis
Interventions
low dose intravenous heparin (LDIVH), Heparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
aflibercept, bevacizumab
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
72
States / cities
Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients

NCT02687204
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
Interventions
Twice daily enoxaparin prophylaxis, Real time dose adjustment
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

NCT00440193
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Little Rock, Arkansas • Redlands, California • Bay Pines, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

NCT04401293
View directory record Official record
Conditions
Sars-CoV2, COVID
Interventions
Enoxaparin, Prophylactic/Intermediate Dose Enoxaparin
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Newark, New Jersey • Bay Shore, New York • Huntington, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 28, 2026, 8:38 AM EDT
Terminated Not applicable Interventional

Exercise Intolerance and Skeletal Muscle Bioenergetics in Children With Deep Venous Thrombosis

NCT04294849
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Magnetic Resonance Imaging, Bicycle Ergometry, Lab Panel, Questionnaires
Other · Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 28, 2026, 8:38 AM EDT
Recruiting Not applicable Interventional

A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease

NCT06695247
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Exercise Training
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

NCT00439725
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 28, 2026, 8:38 AM EDT
Recruiting No phase listed Observational

Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis

NCT06434207
View directory record Official record
Conditions
Congenital Heart Disease, Single-ventricle, Thrombosis
Interventions
Collecting discarded blood samples
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 7 Days
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 28, 2026, 8:38 AM EDT
Completed No phase listed Observational

New York City Mobile Interventional Stroke Team

NCT03048292
View directory record Official record
Conditions
Acute Stroke
Interventions
Acute Endovascular Stroke Treatment
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 28, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 28, 2026, 8:38 AM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 28, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Not applicable Interventional Results available

Determining the Validity of ThinkSono Guidance for Ultrasound Image Acquisition and Remote Detection

NCT06652568
View directory record Official record
Conditions
Deep Vein Thrombosis, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
ThinkSono System
Device
Lead sponsor
ThinkSono, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
634 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

NCT00942968
View directory record Official record
Conditions
Cancer
Interventions
dalteparin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
21
States / cities
Tucson, Arizona • Pleasant Hill, California • Torrance, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 1 Interventional

Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon

NCT00700518
View directory record Official record
Conditions
Raynaud's Phenomenon
Interventions
placebo cream, Glyceryl Trinitrate
Drug
Lead sponsor
Procris Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 29, 2008 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease

NCT04514510
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Isoquercetin, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Results available

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

NCT02584660
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Rivaroxaban, Standard-of-care
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
50
States / cities
Montgomery, Alabama • Chandler, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Sep 28, 2026, 8:38 AM EDT
Completed No phase listed Observational

Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

NCT03404635
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Sep 28, 2026, 8:38 AM EDT
Active, not recruiting Phase 2 Interventional

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

NCT04858776
View directory record Official record
Conditions
Iliofemoral; Thrombosis
Interventions
Perivascular dexamethasone, Perivascular sham
Combination Product
Lead sponsor
Mercator MedSystems, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Darien, Connecticut • Tampa, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 28, 2026, 8:38 AM EDT
Completed No phase listed Observational

Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data

NCT04735523
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Dabigatran, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
5,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 28, 2026, 8:38 AM EDT
Completed No phase listed Observational

Heparin or Enoxaparin in Patients With Cancer

NCT00004875
View directory record Official record
Conditions
Lymphoma, Thromboembolism, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
enoxaparin, heparin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 20, 2011 · Synced Sep 28, 2026, 8:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PFA-100 Responsive to Effect of Energy Drinks on Platelet Function

NCT02997111
View directory record Official record
Conditions
Platelet Function, Thrombosis
Interventions
PFA-100
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 28, 2026, 8:38 AM EDT